In a 48-week phase II clinical trial conducted on patients with type 2 diabetes and obesity, treatment with a dose of 10 mg/kg of bimagrumab resulted in a significant reduction in fat mass by 20.5% (compared to 0.5% in the placebo group), while lean body mass increased by 3.6% (as opposed to a decrease of 0.8% in the placebo group), leading to an overall body weight reduction of -6.5%, which was substantially better than the -0.8% observed in the placebo group
It also flags low-calorie days and prolonged deficits that raise the risk of sarcopenia
Hospitalization for unstable angina and coronary revascularization were analyzed separately and were not included in the composite endpoint
The participants were required to complete a 90-minute submaximal cycling trial, corresponding to a 70% maximal oxygen intake
Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues Inform patients that the incidence of hypoglycemia may increase when XIGDUO XR is added to an insulin secretagogue (e.g., sulfonylurea) and/or insulin
Bu tedavi usul, zellikle detoksifikasyonu destekleyerek vcudun kendini iyiletirme kapasitesini artrmay hedefler ve bu ekilde pek ok hastaln etkilerini azaltabilir
